Real-World Clinical Effectiveness and Safety of Antifibrotics in Progressive Pulmonary Fibrosis Associated with Rheumatoid Arthritis.

: Interstitial lung disease (ILD) is one of the most severe complications of rheumatoid arthritis (RA). Real-world data on antifibrotic treatment are needed. Our objective was to evaluate the real-world effectiveness and tolerability of antifibrotic agents in patients with progressive fibrosing RA-ILD.

The uremic solute 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) may enhance eryptosis and increase erythrocyte osmotic fragility through potential activation of Piezo1.

Background And Hypothesis: In patients with advanced chronic kidney disease (CKD), the lifespan of red blood cells (RBC) is often shortened, a condition attributed to the "uremic milieu." We reported recently that the uremic solute 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) shares structural similarities with Jedi1, a chemical activator of the mechanosensitive cation channel Piezo1, whose activation increases calcium influx into cells. Against this backdrop, we hypothesized that CMPF may induce premature RBC death (eryptosis) through prolonged CMPF-induced activation of Piezo1 located on RBC.

Mechanical and Fatigue Properties of Ti-6Al-4V Alloy Fabricated Using Binder Jetting Process and Subjected to Hot Isostatic Pressing.

Binder jetting 3D printing is an additive manufacturing technique based on the creation of a part through the selective bonding of powder with an adhesive, followed by a sintering process at high temperature to densify the material and produce parts with acceptable properties. Due to the high initial porosity in the material after sintering, which is typically around 5%, post-sintering treatments are often required to increase the material density and enhance the mechanical and fatigue properties of the final component. This paper focuses on the study of the benefits of hot isostatic pressing (HIP) after sintering on the mechanical and fatigue properties of a binder jetting Ti-6Al-4V alloy.

Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome.

Objective: To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and progressive interstitial lung disease (ASS-ILD).

Methods: Multicentre observational retrospective longitudinal study of a cohort of patients with ASS-ILD that started treatment with RTX due to recurrent or ongoing progressive ILD despite therapy with glucocorticoids and immunosuppressants.

Results: Twenty-eight patients were analyzed.